Intervention Review

You have free access to this content

Skin patch and vaginal ring versus combined oral contraceptives for contraception

  1. Laureen M Lopez1,*,
  2. David A Grimes2,
  3. Maria F Gallo3,
  4. Laurie L Stockton4,
  5. Kenneth F Schulz5

Editorial Group: Cochrane Fertility Regulation Group

Published Online: 30 APR 2013

Assessed as up-to-date: 7 MAR 2013

DOI: 10.1002/14651858.CD003552.pub4


How to Cite

Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD003552. DOI: 10.1002/14651858.CD003552.pub4.

Author Information

  1. 1

    FHI 360, Clinical Sciences, Research Triangle Park, North Carolina, USA

  2. 2

    University of North Carolina, School of Medicine, Obstetrics and Gynecology, Chapel Hill, North Carolina, USA

  3. 3

    Centers for Disease Control and Prevention, Division of Reproductive Health, Atlanta, Georgia, USA

  4. 4

    FHI360, Health Services Research, Research Triangle Park, North Carolina, USA

  5. 5

    FHI 360 and UNC School of Medicine, Quantitative Sciences, Research Triangle Park, North Carolina, USA

*Laureen M Lopez, Clinical Sciences, FHI 360, P.O. Box 13950, Research Triangle Park, North Carolina, 27709, USA. llopez@fhi360.org.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 1 Pregnancy per cycle.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 2 Kaplan-Meier cumulative pregnancy rates (95% CI).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 3 Discontinuation - overall (6 or 13 cycles).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 4 Discontinuation - adverse events (5 or 13 cycles).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 5 Compliance per cycle.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 6 Breakthrough bleeding or spotting (cycle 6).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 7 Breakthrough bleeding or spotting (cycle 13).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 8 Breast discomfort.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 9 Headache.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 10 Nausea.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 11 Dysmenorrhea.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 12 Abdominal pain.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 50/75/125 µg + EE 30/40/30 µg, Outcome 13 Adverse events - total (6 cycles).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 1 Discontinuation - overall (cycle 4): patch NGMN 150 µg + EE 20 µg versus OC.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 2 Discontinuation - overall (cycle 4): patch NGMN 112.5 µg + EE 15 µg versus OC.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 3 Discontinuation - overall (cycle 4): patch NGMN 75 µg + EE 10 µg versus OC.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 4 Discontinuation - adverse events (cycle 4): patch NGMN 150 µg + EE 20 µg versus OC.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 5 Discontinuation - adverse events (cycle 4): patch NGMN 112.5 µg + EE 15 µg versus OC.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 6 Discontinuation - adverse events (cycle 4): patch NGMN 75 µg + EE 10 µg versus OC.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 7 Breakthrough bleeding or spotting (cycle 3): patch NGMN 150 µg + EE 20 µg versus OC.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 8 Breakthrough bleeding or spotting (cycle 3): patch NGMN 112.5 µg + EE 15 µg versus OC.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Skin patches containing norelgestromin + EE versus COC norgestimate 250 µg + EE 35 µg, Outcome 9 Breakthrough bleeding or spotting (cycle 3): patch NGMN 75 µg + EE 10 µg versus OC.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 1 Pregnancy per woman (3 cycles).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 2 Spotting (3 cycles).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 3 Amenorrhea.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 4 Breast tenderness.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 5 Nausea.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 1 Pregnancy per woman.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 2 Kaplan-Meier cumulative pregnancy rates (95% CI).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 3 Discontinuation - overall (6 or 13 cycles).
[Analysis 4.4]
Analysis 4.4. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 4 Discontinuation - adverse events (6 or 13 cycles).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 5 Compliance per cycle.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 6 Breakthrough bleeding and spotting (cycle 3).
[Analysis 4.7]
Analysis 4.7. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 7 Breakthrough bleeding and spotting (cycle 13).
[Analysis 4.8]
Analysis 4.8. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 8 Breast discomfort or pain.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 9 Headache.
[Analysis 4.10]
Analysis 4.10. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 10 Nausea.
[Analysis 4.11]
Analysis 4.11. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 11 Dysmenorrhea.
[Analysis 4.12]
Analysis 4.12. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 12 Abdominal pain.
[Analysis 4.13]
Analysis 4.13. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 13 Vaginitis.
[Analysis 4.14]
Analysis 4.14. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 14 Vomiting.
[Analysis 4.15]
Analysis 4.15. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 15 Adverse events - total.
[Analysis 4.16]
Analysis 4.16. Comparison 4 Skin patch releasing norelgestromin 150 µg + EE 20 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 16 Very satisfied with method.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 1 Discontinuation - adverse events (cycle 6).
[Analysis 5.2]
Analysis 5.2. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 2 Noncompliance per cycle (cycle 6).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 3 Breast tenderness (6 cycles).
[Analysis 5.4]
Analysis 5.4. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 4 Headache (6 cycles).
[Analysis 5.5]
Analysis 5.5. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 5 Migraine (6 cycles).
[Analysis 5.6]
Analysis 5.6. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 6 Nausea (6 cycles).
[Analysis 5.7]
Analysis 5.7. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 7 Dysmenorrhea (6 cycles).
[Analysis 5.8]
Analysis 5.8. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 8 Acne (6 cycles).
[Analysis 5.9]
Analysis 5.9. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 9 Vomiting (6 cycles).
[Analysis 5.10]
Analysis 5.10. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 10 Mood swings (6 cycles).
[Analysis 5.11]
Analysis 5.11. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 11 Depression (6 cycles).
[Analysis 5.12]
Analysis 5.12. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 12 Dizziness (6 cycles).
[Analysis 5.13]
Analysis 5.13. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 13 Fatigue (6 cycles).
[Analysis 5.14]
Analysis 5.14. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 14 Hypertension (6 cycles).
[Analysis 5.15]
Analysis 5.15. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 15 Libido decreased (6 cycles).
[Analysis 5.16]
Analysis 5.16. Comparison 5 Skin patch containing levonorgestrel + EE versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 16 Weight increased (6 cycles).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 1 Pregnancy per woman.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 2 Discontinuation - overall (3 to 12 cycles).
[Analysis 6.3]
Analysis 6.3. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 3 Discontinuation - adverse events (3 or 12 cycles).
[Analysis 6.4]
Analysis 6.4. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 4 Noncompliance per woman.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 5 Early or late withdrawal bleeding (cycle 6).
[Analysis 6.6]
Analysis 6.6. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 6 Early or late withdrawal bleeding (cycle 12).
[Analysis 6.7]
Analysis 6.7. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 7 Spotting or breakthrough bleeding (cycle 6).
[Analysis 6.8]
Analysis 6.8. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 8 Spotting or breakthrough bleeding (cycle 12).
[Analysis 6.9]
Analysis 6.9. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 9 Breakthrough bleeding (cycle 5).
[Analysis 6.10]
Analysis 6.10. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 10 Breast tenderness (cycles 5 & 6).
[Analysis 6.11]
Analysis 6.11. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 11 Breast tenderness (cycle 12).
[Analysis 6.12]
Analysis 6.12. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 12 Headache (cycle 6).
[Analysis 6.13]
Analysis 6.13. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 13 Headache (cycle 12).
[Analysis 6.14]
Analysis 6.14. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 14 Nausea (cycle 6).
[Analysis 6.15]
Analysis 6.15. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 15 Nausea (cycle 12).
[Analysis 6.16]
Analysis 6.16. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 16 Vaginal dryness (cycle 6).
[Analysis 6.17]
Analysis 6.17. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 17 Vaginal dryness (cycle 12).
[Analysis 6.18]
Analysis 6.18. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 18 Vaginal yeast infection/discomfort (cycle 5).
[Analysis 6.19]
Analysis 6.19. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 19 Irritability (cycle 6).
[Analysis 6.20]
Analysis 6.20. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 20 Irritability (cycle 12).
[Analysis 6.21]
Analysis 6.21. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 21 Mood swings (cycle 5).
[Analysis 6.22]
Analysis 6.22. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 22 Depression (cycle 6).
[Analysis 6.23]
Analysis 6.23. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 23 Depression (cycle 12).
[Analysis 6.24]
Analysis 6.24. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 24 Hot flashes (cycle 5).
[Analysis 6.25]
Analysis 6.25. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 25 Mean score for satisfaction with method.
[Analysis 6.26]
Analysis 6.26. Comparison 6 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 100 µg + EE 20 µg, Outcome 26 Planned to use method.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 1 Pregnancy per woman.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 2 Discontinuation - overall (12 cycles).
[Analysis 7.3]
Analysis 7.3. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 3 Discontinuation - adverse events (12 cycles).
[Analysis 7.4]
Analysis 7.4. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 4 Early or late withdrawal bleeding (cycle 6).
[Analysis 7.5]
Analysis 7.5. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 5 Early or late withdrawal bleeding (cycle 12).
[Analysis 7.6]
Analysis 7.6. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 6 Spotting or breakthrough bleeding (cycle 6).
[Analysis 7.7]
Analysis 7.7. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 7 Spotting or breakthrough bleeding (cycle 12).
[Analysis 7.8]
Analysis 7.8. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 8 Breast tenderness (cycle 6).
[Analysis 7.9]
Analysis 7.9. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 9 Breast tenderness (cycle 12).
[Analysis 7.10]
Analysis 7.10. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 10 Headache (cycle 6).
[Analysis 7.11]
Analysis 7.11. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 11 Headache (cycle 12).
[Analysis 7.12]
Analysis 7.12. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 12 Nausea (cycle 6).
[Analysis 7.13]
Analysis 7.13. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 13 Nausea (cycle 12).
[Analysis 7.14]
Analysis 7.14. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 14 Vaginal dryness (cycle 6).
[Analysis 7.15]
Analysis 7.15. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 15 Vaginal dryness (cycle 12).
[Analysis 7.16]
Analysis 7.16. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 16 Irritability (cycle 6).
[Analysis 7.17]
Analysis 7.17. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 17 Irritability (cycle 12).
[Analysis 7.18]
Analysis 7.18. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 18 Depression (cycle 6).
[Analysis 7.19]
Analysis 7.19. Comparison 7 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC gestodene 60 µg + EE 15 µg, Outcome 19 Depression (cycle 12).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC desogestrel 150 µg + EE 20 µg, Outcome 1 Discontinuation - overall (cycle 6).
[Analysis 9.1]
Analysis 9.1. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 1 Pregnancy per woman.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 2 Discontinuation - overall (cycle 12 or 13).
[Analysis 9.3]
Analysis 9.3. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 3 Discontinuation - adverse events (cycle 12 or 13).
[Analysis 9.4]
Analysis 9.4. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 4 Mean breakthrough bleeding or spotting days (cycle 6).
[Analysis 9.5]
Analysis 9.5. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 5 Mean breakthrough bleeding or spotting days (cycle 13).
[Analysis 9.6]
Analysis 9.6. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 6 Breakthrough bleeding or spotting (12 cycles).
[Analysis 9.7]
Analysis 9.7. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 7 No withdrawal bleeding (12 cycles).
[Analysis 9.8]
Analysis 9.8. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 8 Breast pain.
[Analysis 9.9]
Analysis 9.9. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 9 Headache.
[Analysis 9.10]
Analysis 9.10. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 10 Nausea.
[Analysis 9.11]
Analysis 9.11. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 11 Dysmenorrhea.
[Analysis 9.12]
Analysis 9.12. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 12 Vaginitis.
[Analysis 9.13]
Analysis 9.13. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 13 Leukorrhea.
[Analysis 9.14]
Analysis 9.14. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 14 Acne.
[Analysis 9.15]
Analysis 9.15. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 15 Vomiting.
[Analysis 9.16]
Analysis 9.16. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 16 Emotional lability.
[Analysis 9.17]
Analysis 9.17. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 17 Decreased libido.
[Analysis 9.18]
Analysis 9.18. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 18 Weight increase.
[Analysis 9.19]
Analysis 9.19. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 19 Total number of adverse events (cycle 12).
[Analysis 9.20]
Analysis 9.20. Comparison 9 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC drospirenone 3 mg + EE 30 µg, Outcome 20 Satisfied or very satisfied with method.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 1 Pregnancy per woman.
[Analysis 10.2]
Analysis 10.2. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 2 Discontinuation.
[Analysis 10.3]
Analysis 10.3. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 3 Compliance: perfect use (3 months).
[Analysis 10.4]
Analysis 10.4. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 4 Frequent bleeding (> 4 episodes of bleeding or spotting).
[Analysis 10.5]
Analysis 10.5. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 5 Irregular bleeding (bleeding-free interval > 17 days).
[Analysis 10.6]
Analysis 10.6. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 6 Prolonged bleeding (bleeding or spotting episode lasting >= 10 days).
[Analysis 10.7]
Analysis 10.7. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 7 Satisfied or very satisfied with method.
[Analysis 10.8]
Analysis 10.8. Comparison 10 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 180/215/250 µg + EE 25 µg, Outcome 8 Planned to use method.
[Analysis 11.1]
Analysis 11.1. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 1 Pregnancy per woman.
[Analysis 11.2]
Analysis 11.2. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 2 Pregnancy per cycle.
[Analysis 11.3]
Analysis 11.3. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 3 Discontinuation - overall (6 or 13 cycles).
[Analysis 11.4]
Analysis 11.4. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 4 Discontinuation - adverse events (6 or 13 cycles).
[Analysis 11.5]
Analysis 11.5. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 5 Compliance per cycle.
[Analysis 11.6]
Analysis 11.6. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 6 Breakthrough bleeding (cycle 6).
[Analysis 11.7]
Analysis 11.7. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 7 Breakthrough spotting (cycle 6).
[Analysis 11.8]
Analysis 11.8. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 8 Breakthrough bleeding (cycle 13).
[Analysis 11.9]
Analysis 11.9. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 9 Breakthrough spotting (cycle 13).
[Analysis 11.10]
Analysis 11.10. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 10 Nausea.
[Analysis 11.11]
Analysis 11.11. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 11 Breast tenderness or pain.
[Analysis 11.12]
Analysis 11.12. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 12 Headache.
[Analysis 11.13]
Analysis 11.13. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 13 Dysmenorrhea.
[Analysis 11.14]
Analysis 11.14. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 14 Abdominal pain.
[Analysis 11.15]
Analysis 11.15. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 15 Vaginitis.
[Analysis 11.16]
Analysis 11.16. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 16 Genital pruritus.
[Analysis 11.17]
Analysis 11.17. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 17 Leukorrhea.
[Analysis 11.18]
Analysis 11.18. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 18 Urinary tract infection.
[Analysis 11.19]
Analysis 11.19. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 19 Acne.
[Analysis 11.20]
Analysis 11.20. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 20 Nervousness.
[Analysis 11.21]
Analysis 11.21. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 21 Depression.
[Analysis 11.22]
Analysis 11.22. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 22 Dizziness.
[Analysis 11.23]
Analysis 11.23. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 23 Libido decrease.
[Analysis 11.24]
Analysis 11.24. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 24 Weight increase.
[Analysis 11.25]
Analysis 11.25. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 25 Increased glucocorticoids.
[Analysis 11.26]
Analysis 11.26. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 26 Sinusitis.
[Analysis 11.27]
Analysis 11.27. Comparison 11 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 27 Leg pain.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 1 Pregnancy per woman (3 cycles).
[Analysis 12.2]
Analysis 12.2. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 2 Compliance per woman.
[Analysis 12.3]
Analysis 12.3. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 3 Amount of blood in period - worse.
[Analysis 12.4]
Analysis 12.4. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 4 Bothersome side effects - worse.
[Analysis 12.5]
Analysis 12.5. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 5 Headaches - worse.
[Analysis 12.6]
Analysis 12.6. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 6 Nausea - worse.
[Analysis 12.7]
Analysis 12.7. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 7 Cramping in periods - worse.
[Analysis 12.8]
Analysis 12.8. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 8 PMS - worse.
[Analysis 12.9]
Analysis 12.9. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 9 Discharge - worse.
[Analysis 12.10]
Analysis 12.10. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 10 Acne - worse.
[Analysis 12.11]
Analysis 12.11. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 11 Moodiness - worse.
[Analysis 12.12]
Analysis 12.12. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 12 Depresssion - worse.
[Analysis 12.13]
Analysis 12.13. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 13 Sex drive - worse.
[Analysis 12.14]
Analysis 12.14. Comparison 12 Vaginal ring releasing etonogestrel 120 µg + EE 15 µg versus COC norgestimate 250 µg + EE 35 µg, Outcome 14 Weight - worse.
[Analysis 13.1]
Analysis 13.1. Comparison 13 Vaginal ring releasing nestorone 150 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 1 Pregnancy.
[Analysis 13.2]
Analysis 13.2. Comparison 13 Vaginal ring releasing nestorone 150 µg + EE 15 µg versus COC levonorgestrel 150 µg + EE 30 µg, Outcome 2 Discontinuation - overall (cycle 3).